Get the Stockscreener App
5.50
0.73%
0.04
After Hours:
5.50
Helus Pharma Inc stock is traded at $5.50, with a volume of 443.24K.
It is up +0.73% in the last 24 hours and up +18.53% over the past month.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
See More
Previous Close:
$5.46
Open:
$5.57
24h Volume:
443.24K
Relative Volume:
0.58
Market Cap:
$274.42M
Revenue:
-
Net Income/Loss:
$-122.31M
P/E Ratio:
-1.2181
EPS:
-4.5151
Net Cash Flow:
$-110.41M
1W Performance:
+4.76%
1M Performance:
+18.53%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$5.43
$5.57
1-Week Range:
$5.10
$5.65
52-Week Range:
$4.29
$8.5498
Helus Pharma Inc Stock (HELP) Company Profile
Compare HELP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HELP
Helus Pharma Inc
|
5.50 | 272.42M | 0 | -122.31M | -110.41M | -4.5151 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Helus Pharma Inc Stock (HELP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-26 | Initiated | Jefferies | Buy |
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Nov-19-21 | Downgrade | Maxim Group | Buy → Hold |
Helus Pharma Inc Stock (HELP) Latest News
Cybin Inc (HELP) reports positive phase 2 anxiety study data - MSN
HELP Initiated Coverage by TD Cowen -- Price Target Set at $8 - GuruFocus
Helus Pharma stock initiated at Buy by TD Cowen on MDD data - Investing.com Canada
Helus Pharma (HELP) Stock Analysis Report | Financials & Insights - Benzinga
HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights - ADVFN
symbol__ Stock Quote Price and Forecast - CNN
Cybin Inc (NASDAQ:HELP) - intelligentinvestor.com.au
HELP Should I Buy - Intellectia AI
HELP Stock Price, Quote & Chart | CYBIN INC (NASDAQ:HELP) - ChartMill
Millennium Management LLC Increases Stake in Helus Pharma Inc - GuruFocus
Cybin Inc (HELP) Reports Positive Phase 2 Anxiety Study Data - Insider Monkey
5 Best Psychedelic Stocks to Buy in 2026 - Insider Monkey
Helus Pharma appoints Michael Cola as CEO - MSN
Help stock crashes on anxiety trial results, but here’s why Jefferies sees up to 200% upside - MSN
Helus Pharma reports encouraging Phase 2 results for HLP004 anxiety treatment - MSN
Helus Pharma (CYBN) appoints Jill Conwell as Chief People Officer - Stock Titan
Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer - Bitget
Helus Pharma Adds Chief People Officer as Mental Health Pipeline Advances - TipRanks
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions - Investing News Network
Neuropsychiatric Innovation Draws Big Pharma Interest and Fresh Investment - Baystreet.ca
HELP Stock Price and Chart — NEO:HELP - TradingView
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
A Look At Cybin (HELP) Valuation After Positive Phase 2 HLP004 Anxiety Data - Yahoo Finance
Assessing Cybin (HELP) Valuation After HLP004 Phase 2 Anxiety Data Draws Fresh Attention - simplywall.st
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results - Yahoo Finance
Cybin (HELP) Is Down 27.3% After Positive HLP004 GAD Phase 2 Data Reported Is The Thesis Intact? - Yahoo Finance
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder - Sahm
Could Helus Pharma’s HLP004 Data Quietly Reframe Cybin’s (HELP) Interventional Psychiatry Investment Story? - simplywall.st
HELP Stock Crashes On Anxiety Trial Results, But Here’s Why Jefferies Sees Up To 200% Upside - Asianet Newsable
HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism - Stocktwits
Helus Pharma’s top-line Phase II data signal detection study for HLP004 - The Pharma Letter
Jefferies reiterates Helus Pharma stock rating on anxiety data By Investing.com - Investing.com Canada
Agencia de ComunicacãoHelus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder - Estadão Blue Studio
Helus Pharma Stock Tumbles As Anxiety Drug Study DisappointsHelus Pharma (NASDAQ:HELP) - Benzinga
Helus Pharma Inc Stock (HELP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):